PATIENTS
Opna Bio is dedicated to discovering and developing novel treatments for cancer patients everywhere. Through evaluating investigational therapeutics in clinical trials, the scientific community is able to assess the safety and efficacy of novel agents. Opna Bio is collaborating with top physicians across the world to ensure information about our clinical trials is easily accessible to patients and their care team. We are grateful to the patients, doctors and study teams who have contributed to our goal of unlocking a cure. See below for a list of our current trials.
Clinical Trial Information
Description
Investigation of the combination of PLX2853 with ruxolitinib in patients with intermediate- or high-risk myelofibrosis not receiving an adequate response with ruxolitinib alone
Principal Investigator
Adam Mead, MD
Sites
United Kingdom
University Hospital of Wales, Cardiff; Nottingham City Hospital; Churchill Hospital, Oxford; St. James’ Hospital, Leeds; University College Hospital, London; Belfast City Hospital; pending additional sites
Description
A Single Arm, Open Label, Phase 1 Study of Novel BET inhibitor PLX51107 and Corticosteroids for Treatment-Refractory Acute GVHD
Principal Investigator
Hannah Choe, MD
Sites
United States
Ohio State University
Expanded Access
Opna Bio is committed to the safety and treatment of all patients including those who may benefit from receiving Opna's investigational products, but who do not qualify for a clinical trial. In order for Expanded Access (also known as Compassionate Use) of investigational agents to be granted, the following conditions must be met:- The patient to be treated must have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to treat the disease or condition;
- The potential patient benefit justifies the potential risks of the treatment use and those potential risks are not unreasonable in the context of the disease or condition to be treated;
- Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval of the expanded access use or otherwise compromise the potential development of the expanded access use.
Contact for requests:
